OX2 Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD200AR-L / OX2 Therap
NCT04642937: Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

Active, not recruiting
1
24
US
Treatment with hP1A8
OX2 Therapeutics
Glioblastoma
11/23
11/24
NCT06305910: CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

Recruiting
1
24
US
Treatment with CD200AR-L, Imiquimod, GBM6-AD, Single dose of radiation (300 cGy)
OX2 Therapeutics
Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
09/25
01/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD200AR-L / OX2 Therap
NCT04642937: Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

Active, not recruiting
1
24
US
Treatment with hP1A8
OX2 Therapeutics
Glioblastoma
11/23
11/24
NCT06305910: CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

Recruiting
1
24
US
Treatment with CD200AR-L, Imiquimod, GBM6-AD, Single dose of radiation (300 cGy)
OX2 Therapeutics
Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
09/25
01/27

Download Options